Different measured values for tacrolimus were obtained with different automated immunoassays. We aimed to examine the differences in the blood tacrolimus concentrations measured by the major immunoassay systems commercially available in Japan.
| INTRODUC TI ON

Tacrolimus or FK506 is an immunosuppressant discovered in 1984 by
Fujisawa Pharmaceutical Co. Ltd. This drug has been proven to be effective for the prevention of organ rejection after transplantation and for the treatment of autoimmune diseases. 1, 2 Monitoring the blood tacrolimus concentration is required to adjust the optimal dose in each patient, because of the narrow therapeutic window and large individual variability in tacrolimus pharmacokinetics. Low blood concentrations may result in rejection, while high concentrations may result in infection or nephrotoxicity. In the clinical setting, immunoassays are used to measure the concentrations of tacrolimus in whole blood.
Automatic immunoassay systems that can measure tacrolimus levels in a short time are used for routine monitoring of blood concentrations of tacrolimus. However, it has been reported that the measured results for the same sample vary when measured by different assay systems. 3, 4 Therefore, if a patient moves to another hospital, the blood tacrolimus concentrations cannot be compared if both hospitals used different systems. There is an increasing need to evaluate different immunoassay systems for consistency.
The reagents used in automated immunoassay systems have improved over the years. Flex cartridge TAC reagent has changed antibody, pretreatment reagent, and magnetic particle reagent compared to flex cartridge TACR reagent. As a result, TAC improves specificity, extraction efficiency, stability after dissolution than TACR. Hence, there is a possibility that the blood concentrations measured by the current assay systems may differ from those reported previously. 
| PATIENTS AND ME THODS
| Patients
| Automatic immunoassay systems
Tacrolimus concentration in the whole blood was determined by ACMIA using a Dimension™ Xpand Plus analyzer (Siemens Healthcare Diagnostics, Berlin, Germany), EMIT using a Viva-E™ analyzer (Siemens Healthcare Diagnostics), CLIA using an ARCHITECT 
| LC-MS/MS
Tacrolimus whole-blood concentration was determined by LC-MS/ MS according to the method reported by Said et al. 6 Briefly, 1.25 mL of 2.18 ng/mL ascomycin in 0.1% formic acid methanol (internal standard) was added to 50 μL of whole blood in a glass tube. The mixture was then briefly vortexed for 5 minutes, followed by centrifugation at 6000 g for 2 minutes. The extract was subjected to Micro Extraction Packed Sorbent (MEPS) ™ sample preparation. Sample loading was performed using 6 replicate 100-μL aliquots of the di- 
| Statistical analysis
The blood tacrolimus concentration obtained by reference method 
TA B L E 1 Data of intraday and interday validation assay of LC-MS/MS
The ME, MAE, and RMSE were calculated to compare the reproducibility of the immunoassays. Analyses were performed using the Predictive Analysis Software (PASW) Statistics version 18 (SPSS Inc., IL, USA), and MS Excel (Microsoft Corp, Redmond, WA, USA).
| RE SULTS
A total of 118 patients (71 men and 47 women) were included in the study. Their mean age was 52 (range, 13-86) years, and the mean body weight was 57.0 (range, 27.8-91.2) kg ( Table 2 ).
All the 3 commercial immunoassays produced results that were very consistent with those obtained by LC-MS/MS, with good correlation for ACMIA (ACMIA = .75 × LC-MS/MS + 1.34, r 2 = .83; Figure 1A ), EMIT (EMIT = .60 × LC-MS/MS + 3.52, r 2 = .71; Figure 1B ), and CLIA (CLIA = .74 × LC-MS/MS + 2.08, r 2 = .81; Figure 1C ). Table 3 ). In this study, the ME was negative for the ACMIA and positive for CLIA and EMIT.
MAE and RMSE were almost the same for ACMIA and CLIA and lower than those for EMIT.
| D ISCUSS I ON
The blood tacrolimus concentrations measured by the ACMIA, CLIA, and EMIT showed good correlation with those obtained by the LC-MS/MS method. ACMIA and CLIA showed a good correlation when compared directly, but ACMIA and CLIA showed a low correlation with EMIT. However, the regression coefficients of all 3 immunoassays tended to be low. In particular, in this study, due to the different principles of measurement by automated assay systems. As large discrepancies of whole-blood tacrolimus concentrations may arise between medical facilities, it is necessary to specify the method of measurement and obtain cooperation among medical facilities when implementing TDM enforcement of tacrolimus.
In conclusion, the present study indicated that the results of the 3 commercial assays were consistent with those of LC-MS/MS, and validation showed acceptable performance for the 3 assays. The ACMIA and CLIA provide considerably better results than the EMIT for monitoring blood tacrolimus levels.
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